DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Inactivation of the PHD3-FOXO3 axis blunts the type I interferon response in microglia and ameliorates Alzheimer's disease progression
Microglia respond to Alzheimer’s disease (AD) with varied transcriptional responses. We show that oligomeric Aß (oAß) induces the expression of Hif1a and Egln3 in microglia in vitro, together with the transcription of the type I interferon signature (IFNS) genes in a PHD3-dependent manner. We identify FOXO3 as a repressor of IFNS, whose abundance decreases upon PHD3 induction in response to oAß. In vivo, loss of PHD3 correlates with abrogation of the IFNS and activation of the disease-associated microglia signature, an increase in microglia proximity to Aß plaques and phagocytosis of both Aß and small plaques. PHD3 deficiency mitigated the Aß plaque–associated neuropathology and rescued behavioral deficits of an AD mouse model. Last, we demonstrate that microglial PHD3 overexpression in the absence of Aß pathology is sufficient to induce the IFNS and behavioral alterations. Together, our data strongly indicate that the inactivation of the PHD3-FOXO3 axis controls the microglial IFNS in a cell autonomous manner, improving AD outcome., This work was supported by grants to A.P., J.V., A.M.M.-C., and A.B.M.-M. by MCIN/AEI/10.13039/501100011033 and ERDF/EU, ISCIII (FORT23/00008 to A.P. and PI21/00915 to J.V.), and FEDER (RTI2018-096629-B-100, PID2021-126894OB-I00, PID2019-109046GA-I00, and PID2022-136526OB-I00; and “FEDER Una manera de hacer Europa,” SAF2017-90794-REDT, and PIE13/0004); by the regional Government of Andalucia (“Proyectos de Excelencia” P12-CTS-2138, P20_01312; Biotechnology Plan applied to Health PRTR-C17.I1; FEDER Andalucia 2014-2020, US-1261055) co-funded by CEC, REC_EU, and FEDER funds; and by the “Ayuda de Biomedicina 2018,” Fundación Domingo Martínez; and to M.E.C. by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001501), the UK Medical Research Council (FC001501), and the Wellcome Trust (FC001501). R.M.-D. was the recipient of a “Sara Borrell” fellowship from ISCIII (CD09/0007); M.A.S.-G., N.L.-U., C.O-d.S.L., C.R.-M., and S.Q.-C. were recipients of an FPU fellowship from Spanish Ministry of Education, Culture, and Sport (respectively, FPU13/00530, FPU14/02115, AP2010–1598, FPU16/02050, and FPU22/00974); A.H.-G. was the recipient of an FPI fellowship from Spanish Ministry of Education, Culture, and Sport (BES-2010-033886); and B.M.-R. was the recipient of a “Junta de Andalucía” predoctoral fellowship (2021). A.E.R.-N. was recipient of JdlC-F fellowship from MCIN/AEI/10.13039/501100011033 (FJCI-2015-23708) and “Contrato de Acceso de I+D+i” from VI PPIT—Universidad de Sevilla. A.B.M.-M. was recipient of the RyC program RYC-2017-22594. J.M.B.-R. was recipient of a 2019-FPI fellowship., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-096629-B-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-126894OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-109046GA-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136526OB-I00
DOI: http://hdl.handle.net/10261/400714, https://api.elsevier.com/content/abstract/scopus_id/105007122484
HANDLE: http://hdl.handle.net/10261/400714, https://api.elsevier.com/content/abstract/scopus_id/105007122484